MedTrace Logo

Study of RPT193 in Healthy Adult Male Subjects

NCT06087978 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2023-11-29

No results posted yet for this study

Summary

Phase 1, open-label, absorption, metabolism, excretion, and mass balance study.

Conditions

  • Healthy Male Subjects

Interventions

DRUG

14C RPT193

Radiolabelled RPT193

Sponsors & Collaborators

  • RAPT Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-05
Primary Completion
2023-10-12
Completion
2023-10-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06087978 on ClinicalTrials.gov